298 related articles for article (PubMed ID: 19155967)
1. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
4. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
6. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of mammalian target of rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case-control study.
Alamo JM; Bernal C; Marín LM; Suárez G; Serrano J; Barrera L; Sousa JM; Padillo FJ; Gómez-Bravo MA
Transplant Proc; 2012 Sep; 44(7):2089-92. PubMed ID: 22974919
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
[TBL] [Abstract][Full Text] [Related]
9. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
[TBL] [Abstract][Full Text] [Related]
10. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
11. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
12. [Cancer after kidney transplantation].
Sandrini S; Setti G; Bossini N; Maiorca P
G Ital Nefrol; 2004; 21 Suppl 26():S67-73. PubMed ID: 15732048
[TBL] [Abstract][Full Text] [Related]
13. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
[TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
15. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
[TBL] [Abstract][Full Text] [Related]
16. [Lymphoproliferative disease and cancer in the transplant patient].
Herreros J; Flórez S; Echevarría JR; Fernández AL; Pardo Mindán FJ
Rev Esp Cardiol; 1995; 48 Suppl 7():129-34. PubMed ID: 8775827
[TBL] [Abstract][Full Text] [Related]
17. Minimizing the risk of posttransplant malignancy.
Campistol JM
Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
[TBL] [Abstract][Full Text] [Related]
18. Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma.
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Varo-Pérez E
Transplant Proc; 2011 Apr; 43(3):711-3. PubMed ID: 21486580
[TBL] [Abstract][Full Text] [Related]
19. Minimizing the risk of posttransplant malignancy.
Campistol JM
Transplantation; 2009 Apr; 87(8 Suppl):S19-22. PubMed ID: 19384182
[TBL] [Abstract][Full Text] [Related]
20. Malignancy after solid organ transplantation: an overview.
Zafar SY; Howell DN; Gockerman JP
Oncologist; 2008 Jul; 13(7):769-78. PubMed ID: 18614590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
